Mind Medicine (MindMed) (MNMD) Stock Forecast & Price Target

$7.13 -0.39 (-5.19%)

(As of 02:08 PM ET)

Mind Medicine (MindMed) - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 12 Analyst Ratings

Sell
0

Hold
0

Buy
12

Based on 12 Wall Street analysts who have issued ratings for Mind Medicine (MindMed) in the last 12 months, the stock has a consensus rating of "Buy." Out of the 12 analysts, 9 have given a buy rating, and 3 have given a strong buy rating for MNMD.

Consensus Price Target

$25.38
255.89% Upside

According to the 12 analysts' twelve-month price targets for Mind Medicine (MindMed), the average price target is $25.38. The highest price target for MNMD is $55.00, while the lowest price target for MNMD is $9.00. The average price target represents a forecasted upside of 255.89% from the current price of $7.13.

Get the Latest News and Ratings for MNMD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Mind Medicine (MindMed) and its competitors.

MNMD Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	3 Strong Buy rating(s)	3 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	9 Buy rating(s)	9 Buy rating(s)	7 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$25.38	$25.38	$24.14	$25.43
Forecasted Upside	255.89% Upside	302.14% Upside	301.04% Upside	824.68% Upside
Consensus Rating	Buy	Buy	Buy	Buy

917 Trades… Zero Losses? (Ad)

As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”

Go here to see how you can start accessing these opportunities today

MNMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MNMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Mind Medicine (MindMed) Stock vs. The Competition

Type	Mind Medicine (MindMed)	Medical Companies	S&P 500
Consensus Rating Score	3.25	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	255.89% Upside	26,623.65% Upside	8.50% Upside
News Sentiment Rating	Positive News See Recent MNMD News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/11/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00	+547.82%
10/14/2024	Leerink Partners 1 of 5 stars		Initiated Coverage	Outperform	$20.00	+266.30%
10/11/2024	Leerink Partnrs 5 of 5 stars	M. Goodman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/16/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$16.00 ➝ $14.00	+122.58%
7/24/2024	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Wittes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/24/2024	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy ➝ Buy	$36.00 ➝ $36.00	+307.24%
Get the Latest News and Ratings for MNMD and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Mind Medicine (MindMed) and its competitors with MarketBeat's FREE daily newsletter.
6/21/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight
6/5/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$22.00 ➝ $22.00	+212.94%
5/29/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Beatty Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/28/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$27.00	+223.35%
5/13/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$29.00 ➝ $20.00	+121.24%
4/14/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$21.00	+510.46%
12/15/2022	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$21.00	+701.52%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:27 PM ET.

MNMD Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Mind Medicine (MindMed) is $25.38, with a high forecast of $55.00 and a low forecast of $9.00.
: 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mind Medicine (MindMed) in the last year. There are currently 9 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MNMD shares.
: According to analysts, Mind Medicine (MindMed)'s stock has a predicted upside of 255.89% based on their 12-month stock forecasts.
: Over the previous 90 days, Mind Medicine (MindMed)'s stock had 1 upgrade by analysts.
: Mind Medicine (MindMed) has been rated by research analysts at Canaccord Genuity Group, HC Wainwright, Leerink Partners, and Leerink Partnrs in the past 90 days.
: Analysts like Mind Medicine (MindMed) more than other "medical" companies. The consensus rating for Mind Medicine (MindMed) is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MNMD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

When it comes to NVDA… “acceleration cycles” are the key (Ad)

Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.

Use this link to see Nvidia Unchained right away!

This page (NASDAQ:MNMD) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mind Medicine (MindMed) (MNMD) Stock Forecast & Price Target